Mitoxantrone, More than Just Another Topoisomerase II Poison

Berberine suppresses gero-conversion from cell cycle arrest to senescence

(2016) Hong Zhao et al.   Aging-US

Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both Topoisomerase II isoforms

(2014) Shiwei Deng et al.   BMC CANCER

Phase I clinical trial of pegylated liposomal mitoxantrone plm60-s: pharmacokinetics, toxicity and preliminary efficacy

(2014) Jianliang Yang et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Proteolytic Degradation of Topoisomerase II (Top2) Enables the Processing of Top2·DNA and Top2·RNA Covalent Complexes by Tyrosyl-DNA-Phosphodiesterase 2 (TDP2)

(2014) Rui Gao et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Nanodiamond–Mitoxantrone Complexes Enhance Drug Retention in Chemoresistant Breast Cancer Cells

(2014) Tan-Boon Toh et al.   MOLECULAR PHARMACEUTICS

Inhibition of c-Abl Kinase Activity Renders Cancer Cells Highly Sensitive to Mitoxantrone

(2014) Kemal Alpay et al.   PLoS One

Mitoxantrone Targets the ATP-binding Site of FAK, Binds the FAK Kinase Domain and Decreases FAK, Pyk-2, c-Src, and IGF-1R In Vitro Kinase Activities

(2013) Vita M. Golubovskaya et al.   Anti-Cancer Agents in Medicinal Chemistry

Inactivation of PTEN increases ABCG2 expression and the side population through the PI3K/Akt pathway in adult acute leukemia

(2013) Fang-Fang Huang et al.   CANCER LETTERS

Topoisomerase 2β: A Promising Molecular Target for Primary Prevention of Anthracycline-Induced Cardiotoxicity

(2013) P Vejpongsa et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Pegylated liposomal mitoxantrone is more therapeutically active than mitoxantrone in L1210 ascitic tumor and exhibits dose-dependent activity saturation effect

(2013) ChunLei Li et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

A New Target for an Old Drug: Identifying Mitoxantrone as a Nanomolar Inhibitor of PIM1 Kinase via Kinome-Wide Selectivity Modeling

(2013) Xiaobo Wan et al.   JOURNAL OF MEDICINAL CHEMISTRY

On the structural basis and design guidelines for type II topoisomerase-targeting anticancer drugs

(2013) Chyuan-Chuan Wu et al.   NUCLEIC ACIDS RESEARCH

Lysine-Specific Demethylase 1 in Breast Cancer Cells Contributes to the Production of Endogenous Formaldehyde in the Metastatic Bone Cancer Pain Model of Rats

(2013) Jia Liu et al.   PLoS One

Application of a Novel Microtitre Plate-Based Assay for the Discovery of New Inhibitors of DNA Gyrase and DNA Topoisomerase VI

(2013) James A. Taylor et al.   PLoS One

A Novel High Throughput Biochemical Assay to Evaluate the HuR Protein-RNA Complex Formation

(2013) Vito G. D’Agostino et al.   PLoS One

Replication-Dependent and Transcription-Dependent Mechanisms of DNA Double-Strand Break Induction by the Topoisomerase 2-Targeting Drug Etoposide

(2013) Margaret Tammaro et al.   PLoS One

A novel small-molecule screening strategy identifies mitoxantrone as a RhoGTPase inhibitor

(2012) Aurélien Bidaud-Meynard et al.   BIOCHEMICAL JOURNAL

Identification of the molecular basis of doxorubicin-induced cardiotoxicity

(2012) Sui Zhang et al.   NATURE MEDICINE

Identification of Potential Small Molecule Binding Pockets on Rho Family GTPases

(2012) Juan Manuel Ortiz-Sanchez et al.   PLoS One

MRE11 facilitates the removal of human topoisomerase II complexes from genomic DNA

(2012) K. C. Lee et al.   Biology Open

Recent Advances in Developing Small Molecules Targeting RNA

(2011) Lirui Guan et al.   ACS Chemical Biology

M2, a novel anthracenedione, elicits a potent DNA damage response that can be subverted through checkpoint kinase inhibition to generate mitotic catastrophe

(2011) Benny J. Evison et al.   BIOCHEMICAL PHARMACOLOGY

Phosphorylation of p53 on Ser15 during cell cycle and caused by Topo I and Topo II inhibitors in relation to ATM and Chk2 activation

(2011) Hong Zhao et al.   CELL CYCLE

Mitoxantrone Inhibits HIF-1  Expression in a Topoisomerase II-Independent Pathway

(2011) Y.-M. Toh et al.   CLINICAL CANCER RESEARCH

Discovery of selective bioactive small molecules by targeting an RNA dynamic ensemble

(2011) Andrew C Stelzer et al.   Nature Chemical Biology

Harnessing synthetic lethal interactions in anticancer drug discovery

(2011) Denise A. Chan et al.   NATURE REVIEWS DRUG DISCOVERY

The MRE11 complex: starting from the ends

(2011) Travis H. Stracker et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Unraveling the mechanism of BRCA2 in homologous recombination

(2011) William K Holloman   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Structural Basis of Type II Topoisomerase Inhibition by the Anticancer Drug Etoposide

(2011) C.-C. Wu et al.   SCIENCE

Oxidative metabolism of the anti-cancer agent mitoxantrone by horseradish, lacto-and lignin peroxidase

(2010) Thomas B. Brück et al.   BIOCHIMIE

Mitoxantrone in combination with an inhibitor of DNA-dependent protein kinase: a potential therapy for high risk B-cell chronic lymphocytic leukaemia

(2010) Sarah L. Elliott et al.   BRITISH JOURNAL OF HAEMATOLOGY

Targeting DNA repair in breast cancer: A clinical and translational update

(2010) Eitan Amir et al.   CANCER TREATMENT REVIEWS

New biomarkers probing depth of cell senescence assessed by laser scanning cytometry

(2010) Hong Zhao et al.   CYTOMETRY PART A

Analysis of t(15;17) chromosomal breakpoint sequences in therapy-related versus de novo acute promyelocytic leukemia: Association of DNA breaks with specific DNA motifs at PML and RARA loci

(2010) Syed Khizer Hasan et al.   GENES CHROMOSOMES & CANCER

Expression of Noncoding Vault RNA in Human Malignant Cells and Its Importance in Mitoxantrone Resistance

(2010) S. C. B. Gopinath et al.   MOLECULAR CANCER RESEARCH

Cardiotoxicity of anticancer treatments: what the cardiologist needs to know

(2010) Michael S. Ewer et al.   Nature Reviews Cardiology

Genotoxic stress causes the accumulation of the splicing regulator Sam68 in nuclear foci of transcriptionally active chromatin

(2010) Roberta Busà et al.   NUCLEIC ACIDS RESEARCH

Tumor Tissue-Derived Formaldehyde and Acidic Microenvironment Synergistically Induce Bone Cancer Pain

(2010) Zhiqian Tong et al.   PLoS One

Can Anthracycline Therapy for Pediatric Malignancies Be Less Cardiotoxic?

(2010) Joy M. Fulbright et al.   Current Oncology Reports

The Centrality of RNA

(2009) Phillip A. Sharp   CELL

PTEN/PI3K/Akt Pathway Regulates the Side Population Phenotype and ABCG2 Activity in Glioma Tumor Stem-like Cells

(2009) Anne-Marie Bleau et al.   Cell Stem Cell

Structural Basis for Stabilization of the Tau Pre-mRNA Splicing Regulatory Element by Novantrone (Mitoxantrone)

(2009) Suxin Zheng et al.   CHEMISTRY & BIOLOGY

Rad52

(2009) Uffe H. Mortensen et al.   CURRENT BIOLOGY

Myeloperoxidase Genotypes and Enhanced Efficacy of Chemotherapy for Early-Stage Breast Cancer in SWOG-8897

(2009) Christine B. Ambrosone et al.   JOURNAL OF CLINICAL ONCOLOGY

Mitoxantrone Analogues as Ligands for a Stem−Loop Structure of Tau Pre-mRNA

(2009) Yang Liu et al.   JOURNAL OF MEDICINAL CHEMISTRY

DNA repair deficiency and neurological disease

(2009) Peter J. McKinnon   NATURE REVIEWS NEUROSCIENCE

Identification and Characterization of Inhibitors of Human Apurinic/apyrimidinic Endonuclease APE1

(2009) Anton Simeonov et al.   PLoS One

Kinetics of histone H2AX phosphorylation and Chk2 activation in A549 cells treated with topotecan and mitoxantrone in relation to the cell cycle phase

(2008) Hong Zhao et al.   CYTOMETRY PART A

Cellular processing pathways contribute to the activation of etoposide-induced DNA damage responses

(2008) Jia-Rong Fan et al.   DNA REPAIR

NK314, a Topoisomerase II Inhibitor That Specifically Targets the α Isoform

(2008) Eriko Toyoda et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Fas-mediated killing of primary prostate cancer cells is increased by mitoxantrone and docetaxel

(2008) J. C. Symes et al.   MOLECULAR CANCER THERAPEUTICS